<?xml version="1.0" encoding="UTF-8"?>
<p id="para140">The full study protocol including the inclusion criteria for each randomisation is available in the 
 <xref rid="sec1" ref-type="sec">appendix (p 34)</xref>. Patients aged at least 18 years and who had symptomatic multiple myeloma or non-secretory multiple myeloma based on bone marrow clonal plasma cells, organ or tissue impairment considered by the clinician to be myeloma related, or paraprotein (M-protein) in serum or urine were eligible for the initial randomisation. Exclusion criteria for the initial randomisation included previous or concurrent malignancies, including myelodysplastic syndromes; previous treatment for myeloma (except local radiotherapy, bisphosphonates, and corticosteroids); grade 2 or worse peripheral neuropathy, acute renal failure (unresponsive to up to 72 h of rehydration, characterised by creatinine &gt;500 Î¼mol/L or urine output &lt;400 mL per day, or requiring dialysis); and active or previous hepatitis C infection.
</p>
